Form 8-K - Current report:
SEC Accession No. 0001213900-25-125413
Filing Date
2025-12-23
Accepted
2025-12-23 16:49:06
Documents
14
Period of Report
2025-12-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0270776-8k_citius.htm   iXBRL 8-K 24169
2 PRESS RELEASE, DATED DECEMBER 23, 2025 ea027077601ex99-1_citius.htm EX-99.1 87649
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12619
  Complete submission text file 0001213900-25-125413.txt   306214

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20251223.xsd EX-101.SCH 3026
5 XBRL LABEL FILE ctxr-20251223_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ctxr-20251223_pre.xml EX-101.PRE 22366
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0270776-8k_citius_htm.xml XML 3206
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 251601363
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)